Anglonordic Life Sciences Conference

A FreeMind Group Supported Event

Anglonordic Life Sciences Conference Banner, May 4-5, 2022, London

Where: London

When: May 4-5, 2022

FreeMind proudly supports BioPartner UK’s Anglonordic Life Science Conference.

Anglonordic is exclusively for European investors and R&D companies from the Nordics and the UK to connect with each other. With an established format of panel discussions, parallel technology and biotech investment rooms, plus 1:1 meetings, this conference provides exceptional value. Investors with funds attend free-of-charge.

The conference will take place on Thursday 5th May 2022 at etc.venues County Hall, London. Networking begins on the evening of Wednesday 4th May 2022, with an exclusive Anglonordic Drinks Reception at the residence of H.E. the Ambassador of Denmark to the UK in central London.

The Anglonordic Life Science Conference has a by-invitation-only policy. The organizers welcome a limited number of service suppliers as sponsors or exhibitors.

Why attend?

MEET decision makers at leading and upcoming drug discovery and technology companies from the UK and Nordic regions, along with investment firms from throughout Europe

LEARN from major investment firms about the current status of European investment in life science technologies

GAIN insights from experienced life science operators within the Anglo-Nordic space

1:1 Partnering is a large part of the conference. Meetings are pre-booked using the globally-renowned Meeting Mojo booking platform. Registered delegates can log in to browse profiles, set their own availability, request meetings, and promote their company to best advantage.


In 2021, attending investors included: 3B Future Health Fund (formerly Helsinn Investment Fund), 4BIO Capital, Advent Life Sciences, Albion Technology & General VCT plc, Alpha Blue Ocean, Alpha Bronze Life Sciences Opportunity Fund, Apollo Ventures, Aratus Capital, Arix Bioscience, Arvic AG, Axilium Holding AB, Axon Capital Partners, BioLucidity Advisors, Bioscience Managers, Biotechnology Business Institute, Bond Asian Ventures Limited, Cascara Ventures Bvba, Catapult Ventures, China Life Franklin Asset Management, Curam Capital Management, DeBere Capital Partners, Deep Science Ventures, Draper Esprit, Eir Ventures, Emerson Collective, ESM Biotech, Esperante, European Investment Bank, GIMV, GL Capital, GreenSky Capital, Hermes Partners Intl Ltd., i2020 Accelerator, Ignite Capital Partners, Inc., Inkef Capital BV, Innovate UK, Inveready Asset Management, IP Group, IPF Partners, Julz Co LLC, Kreos Capital, Kurma Partners SA, Limerston Capital Partners, Longacre Funding Partners Plc, Luminous Ventures, Lundbeckfonden Ventures, M Ventures, Mercia Asset Management, Momentum Biotech, MVM Partners, National Institute for Health Research, NeoMed, New Grounds Venture Capital, Newables and Syndicate Room, Norgine Ventures, Novalis Biotech Acceleration, Novo Holdings, NRW.BANK, o2h Ventures, Optum Ventures, Oxford Technology 3 VCT, Panakes Partners SGRSpa, Pontifax, Questra Limited, RBV Capital, R-Pharm, Rosetta Capital Ltd, Ruffena Capital Ltd, Seroba Life Sciences, Seventure Partners, SHS, SR One, SV Health Investors, Swelife International, Syncona, TRILANTIC EUROPE, UCB Ventures, UK Innovation & Science Seed Fund, V-Bio Ventures, Vickers Venture Partners, Xeraya Capital, and XOventure GmbH.